Skip to main content
OpenTrials
Completed

NCT Number: NCT05324839

A Study of Botulinum Toxin Type A Treatment of Wrinkles in Asian

OBJECTIVES: The aim of this randomized, parallel-group, double-blinded controlled multicenter clinical trial is to determine the proper dosage of botulinum toxin type A in Asian, and provide evidence-based proof.

METHODS: 250 patients were included in this study, first, trained observers assessed their wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale before injecting botulinum toxin type A, then we injected different dosages to patients with the different pre-injection scores. All patients were followed up for up to one year. Logistic regression was built, the chi-square test was performed, and R square and p-value are used for evaluation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

About this study

This was a self-reported, randomized, parallel-group, double-blinded controlled multicenter clinical trial. It was conducted in Wuhan, Shanghai, and Dongguan, China, at the plastic and reconstructive surgery, and approved by the ethics committee of Shanghai Ninth People's Hospital, affiliated to Shanghai Jiao Tong University School of Medicine. All patients were fully informed about the study in accordance with the applicable regulations and International Conference on Harmonisation Good Clinical Practices guidelines and gave written informed consent before the study. The main inclusion criteria were: 1. Chinese males or females aged over 18 years old who want to accept medical removal of the wrinkle; 2. noticeable symmetrical wrinkles on both sides of the face (grade 1-4 on the 5-grade Wrinkles Severity Rating Scale); 3. female patients must take a pregnancy test to prove they are not pregnant, and they are also asked to use a method of contraception 30 days before inclusion into the group and to use a reliable method of contraception throughout the entire study; 4. patients should not accept other forms of cosmetic intervention and agree to refrain from participation in any other clinical trials that may interrupt the study. The main exclusion criteria were: 1. the wrinkle severity of any site or both sites are either grade 0 or 5 on the 5-grade Wrinkle Severity Rating Scale. 2. the presence of facial hair that may influence the observation of wrinkle severity; 3. the area of injection had an apparent acne scar, active inflammation, infection, cancer or premalignancy, or untreated wound; 4. patients who had facial plastic surgery, tissue transplant, silica gel, liposome (fat) injection, or other permanent or semi-permanent dermal filler; 5. patients who had any type of Botox injection in the last year or were injected more than 3 times.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Chinese males or females aged over 18 years old who want to accept medical removal of the wrinkle;
  • 2. Noticeable symmetrical wrinkles on both sides of the face (grade 1-4 on the 5-grade Wrinkles Severity Rating Scale);
  • 3. Female patients must take a pregnancy test to prove they are not pregnant, and they are also asked to use a method of contraception 30 days before inclusion into the group and to use a reliable method of contraception throughout the entire study;
  • 4. Patients should not accept other forms of cosmetic intervention and agree to refrain from participation in any other clinical trials that may interrupt the study.

Exclusion criteria

  • 1. The wrinkle severity of any site or both sites are either grade 0 or 5 on the 5-grade Wrinkle Severity Rating Scale.
  • 2. The presence of facial hair that may influence the observation of wrinkle severity;
  • 3. The area of injection had an apparent acne scar, active inflammation, infection, cancer or premalignancy, or untreated wound;
  • 4. Patients who had facial plastic surgery, tissue transplant, silica gel, liposome (fat) injection, or other permanent or semipermanent dermal filler;
  • 5. Patients who had any type of Botox injection in the last year or were injected more than 3 times.

Treatment and study plan

Botulinum Toxin Type A

Drug

injecting different dosage to different group

Primary outcomes

  1. The change of wrinkle serenity rating scale after 2 weeks

    Time frame: Two weeks after injecting BoNTA

    Compare wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale 2 weeks after Botox injection

  2. The change of wrinkle serenity rating scale after one month

    Time frame: One month after injecting BoNTA

    Compare wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale one month after Botox injection

  3. The change of wrinkle serenity rating scale after three months

    Time frame: Three months after injecting BoNTA

    Compare wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale three months after Botox injection

  4. The change of wrinkle serenity rating scale after six months

    Time frame: Six months after injecting BoNTA

    Compare wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale six months after Botox injection

  5. The change of wrinkle serenity rating scale after nine months

    Time frame: Nine months after injecting BoNTA

    Compare wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale nine months after Botox injection

  6. The change of wrinkle serenity rating scale after one year

    Time frame: One year after injecting BoNTA

    Compare wrinkle severity according to the 5-grade Wrinkle Severity Rating Scale one year after Botox injection

Sponsors and collaborators

Lead sponsor

Shanghai Jiao Tong University School of Medicine

Other

Registry information

Official study title

A Multicenter, Prospective, Double-Blinded, Randomized, Parallel-Group, Dose-Ranging Study of Botulinum Toxin Type A Treatment of Wrinkles in Asian

Important dates

Study start
2014
Primary completion
2014
Study completion
2017
First posted
Apr 12, 2022
Registry last updated
Apr 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.